Research guide · Metabolic Support
Retatrutide — research protocol
Triple agonist compound for comprehensive metabolic regulation.
This guide summarizes study areas and sources associated with the compound. BioPeptideX does not convert experimental information into a clinical regimen or recommend an individual dose, frequency, route or duration.
Catalog presentations
Concentration table
Mathematical reference only; this is not a dosing recommendation.
Research areas
- GIP/GLP-1/Glucagon triple agonist
- Lyophilized for stability
- 99% HPLC purity
Most-cited research protocols
Educational information based on research protocols and literature; it does not replace guidance from a healthcare professional.
Retatrutide is an investigational triple hormone receptor agonist activating GIP, GLP-1, and glucagon receptors, currently in Phase 3 trials for obesity and related conditions. It is not FDA-approved.
| Dose | Frequency | Duration | Route | |
|---|---|---|---|---|
| Phase 3 Trial Design | 2 mg starting dose, escalated to 4 mg, 9 mg, or 12 mg | Once weekly | Dose increases every 4 weeks until target dose is reached | Subcutaneous injection |
Cycle: Each titration phase is 4 weeks long to allow steady-state plasma concentrations to be reached.
Benefits and research observations: Monitor for nausea, vomiting, diarrhea, heart rate changes, and liver enzymes, especially during dose escalations.
Handling and storage
Store unreconstituted product according to its label and maintain the cold chain where applicable. After any preparation, follow only validated instructions for the specific product and diluent. Do not use if packaging is damaged or the solution shows particles or unexpected changes.
Warnings
Do not use this page for self-diagnosis or self-medication. Pregnancy, breastfeeding, minors, cancer history, allergies, active disease and concurrent treatments require individual professional evaluation.
Published sources
- 1.Jastreboff AM, et al. NEJM, 2023.
- 2.Rosenstock J, et al. Lancet, 2023.